null

null

null

null

null

null

null

null

null

null

null

null

null

-15.14x Total Debt / Equity (Negative equity)

Moderate; ~$1.1B convertible notes at fixed rates limit floating-rate exposure, but 20bps rise increases cost on any variable credit facility by ~$2M annually

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Semiconductor/microfluidic chip manufacturing concentrated in Taiwan/South Korea; rare-earth reagent inputs reliant on Chinese chemical supply chains

Limited international revenue (~5-8% of total); primary exposure in Europe (EUR) and Japan (JPY); currency devaluation risk is modest but hedging infrastructure is underdeveloped

~92% US revenue; Europe and Japan are top international markets; EUR and JPY devaluation pose limited but growing risk as ex-US expansion accelerates

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Illumina historically represented critical sequencing platform dependency; post-diversification efforts ongoing but Illumina still near or above 30% of sequencing input cost

Significant operational disruption; SHIELD and Reveal liquid biopsy platforms rely on cloud-based bioinformatics pipelines; 30-day migration would halt test reporting

Secondary fallback feasible within 60-90 days via multi-cloud architecture, but HIPAA-compliant data migration of genomic datasets adds 2-3 months minimum

High API coupling risk to Illumina sequencing APIs and internal bioinformatics stack; physician EHR integrations (Epic, Cerner) create moderate lock-in for ordering workflows

Low Howey Test risk; revenue model is fee-for-service diagnostic testing, not an investment contract; no tokenized or profit-sharing instrument present

Very High

High GDPR exposure as genomic data is sensitive health data under Article 9; CCPA compliance required for California patients; cross-border genomic data transfer poses regulatory risk

Moderate; growing dominance in liquid biopsy oncology diagnostics may attract scrutiny; Illumina/GRAIL precedent heightens regulatory sensitivity in genomic diagnostics consolidation

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

~85% transactional (fee-per-test reimbursement); ~15% recurring via pharma biopharma development services contracts; low subscription base currently

Per-test fee reimbursement from Medicare/Medicaid and private payers plus biopharma development services milestone and sample-processing fees

Test pricing ~$3,500-$5,000 per liquid biopsy; reimbursement-constrained by CMS rates; limited ability to raise prices above LCD coverage thresholds without volume offset

Moderate-low; pricing largely dictated by CMS reimbursement schedules and payer contracts; clinical utility differentiation provides some premium over competitors

Current gross margin ~25-35%; long-term target 60-70% as volume scales and sequencing cost per test declines with throughput and technology improvements

Low free-rider risk; liquid biopsy tests are prescribed and reimbursed; physicians cannot access proprietary algorithms without ordering through Guardant's clinical laboratory

Sublinear at scale; lab processing is partially automatable and bioinformatics pipelines are software-driven; sales force growth is headcount-linear but lab ops scale better

Marginal cost of additional test is primarily reagent and sequencing cost (~$500-800/test); software interpretation and reporting costs near-zero marginal, improving unit economics at scale

Not applicable; Guardant operates a centralized CLIA-certified laboratory model, not a franchise network

At 10x scale, CAC efficiency improves as physician network effects compound; current CAC estimated ~$800-1,200 per ordering physician; LTV/CAC likely exceeds 5x at scale

Weak direct network effects; stronger data network effect as larger genomic dataset improves algorithm accuracy and companion diagnostic partnerships, creating defensible moat over time

-20.7% Return on Assets (Negative equity)

Tier 2 resilient; oncology diagnostics are non-discretionary for cancer patients; risk lies in reimbursement policy changes and hospital budget cuts affecting test ordering volume

Oncologists and cancer care physicians ordering liquid biopsy for therapy selection and monitoring; top 20% of ordering physicians likely represent 60%+ of volume

Biopharma and biotech companies using Guardant360 CDx as companion diagnostic in clinical trials and drug development programs; 5-8 major pharma relationships

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

4.9% CapEx / Revenue (Low-CapEx Asset-Light)

0001576280

GH